|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's range||276.68 - 297.72|
|52-week range||54.10 - 297.72|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||52.27|
|Earnings date||09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||200.87|
Dr. Calvin Sun,The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is...
Coronavirus stock BioNTech (NASDAQ: BNTX) was a winner on Monday. BioNTech announced Monday that it has launched a project aimed at developing a malaria vaccine based on the messenger RNA (mRNA) technology that underpins BNT162b2. The biotech said this program, "will assess multiple vaccine candidates featuring known Malaria targets ... as well as new antigens discovered in the pre-clinical research phase."